IMR Press / RCM / Volume 25 / Issue 4 / DOI: 10.31083/j.rcm2504127
Open Access Review
The Role of Ferroptosis in Atrial Fibrillation: A Promising Future
Show Less
1 Department of Cardiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, 214023 Wuxi, Jiangsu, China
*Correspondence: (Ru-Xing Wang)
These authors contributed equally.
Rev. Cardiovasc. Med. 2024, 25(4), 127;
Submitted: 8 October 2023 | Revised: 30 November 2023 | Accepted: 8 December 2023 | Published: 1 April 2024
(This article belongs to the Section Heart Diseases)
Copyright: © 2024 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, with its diagnosis being closely tied to higher rates of cardiovascular morbidity and mortality. AF is associated with a range of dangerous complications including stroke and heart failure, making it a key driver of healthcare spending and a major threat to global public health. The precise mechanisms that govern AF incidence and the onset of related complications, however, remain uncertain. Ferroptotic cell death has been the focus of rising interest in the cardiac arrhythmias, and there is recent evidence supporting a role for atrial ferroptosis as a mediator of AF development. Interventional strategies focused on ferroptotic activity, such as novel ferroptosis inhibitors, have also shown promise as a means of protecting against AF through their ability to reduce iron overload. In this review, we provide a summary of the proposed mechanisms whereby ferroptosis contributes to the pathophysiology of AF and their therapeutic implications.

atrial fibrillation
therapeutic implication
82370342/National Natural Science Foundation of China
BK20231145/Natural Science Foundation of Jiangsu Province
Fig. 1.
Back to top